E Fund Management’s Karyopharm Therapeutics KPTI Stock Holding History

E Fund Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,457	Closed	-$202K	–	327
2023 Q1	$202K	Buy	3,457 +1,023	+42%	+$50.5K	0.01%	299
2022 Q4	$124K	Sell	2,434 -628	-21%	-$43.5K	0.01%	322
2022 Q3	$251K	Sell	3,062 -449	-13%	-$33.5K	0.02%	263
2022 Q2	$238K	Buy	3,511 +806	+30%	+$73.9K	0.02%	266
2022 Q1	$299K	Buy	2,705 +1,879	+227%	+$234K	0.01%	197
2021 Q4	$80K	Sell	826 -542	-40%	-$54K	﹤0.01%	292
2021 Q3	$119K	Buy	+1,368	New	+$142K	0.01%	257
2021 Q1	$118K	Buy	+751	New	+$158K	0.01%	235

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

E Fund Management's KPTI Position: Q2 2023 in Review

E Fund Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 3,457 shares — an estimated $202K sold.

E Fund Management first reported a position in KPTI in Q1 2021 and held it in 8 quarters. The position peaked at $299K in Q1 2022. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

E Fund Management reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
E Fund Management sold 3,457 Karyopharm Therapeutics shares in Q2 2023, an estimated $202K.
E Fund Management first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 8 quarters.
E Fund Management's Karyopharm Therapeutics position peaked at $299K in Q1 2022.
137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on E Fund Management's 13F filing for Q2 2023, filed 11 Aug 2023.